TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma
This study integrates ex vivo drug sensitivity profiling, genomics, transcriptomics, and proteomics across 167 CD138+ bone marrow patient samples to characterize TP53-associated vulnerabilities and provides new insights into refining TP53 classification to optimize treatment strategies for high-risk MM.